Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
OtherErratum

Erratum to Simultaneous inhibition of PI3Ka and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer

Yuxiang Wang, Xian Li, Xueling Liu, Yi Chen, Chunhao Yang, Cun Tan, Bobo Wang, Yiming Sun, Xi Zhang, Yinglei Gao, Jian Ding and Linghua Meng
Cancer Biology & Medicine November 2019, 16 (4) 836; DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0401
Yuxiang Wang
1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2University of Chinese Academy of Sciences, Beijing 100049, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xian Li
1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xueling Liu
1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2University of Chinese Academy of Sciences, Beijing 100049, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Chen
2University of Chinese Academy of Sciences, Beijing 100049, China
3Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunhao Yang
4Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cun Tan
4Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bobo Wang
1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiming Sun
2University of Chinese Academy of Sciences, Beijing 100049, China
3Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xi Zhang
1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yinglei Gao
2University of Chinese Academy of Sciences, Beijing 100049, China
3Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Ding
2University of Chinese Academy of Sciences, Beijing 100049, China
3Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected] [email protected]
Linghua Meng
1Division of Anti-Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
2University of Chinese Academy of Sciences, Beijing 100049, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected] [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

In the published Figure 11, errors appeared in Figure 1B on page 69. In Figure 1B, bands for p-Akt S473, Akt, and Actin in H1355 cells were mistakenly placed. Here, we have updated Figure 1B to correct the mistake above. The errors do not impact the conclusions of this article. We apologize for the errors and for any confusion it may have caused.

1B
  • Download figure
  • Open in new tab
  • Download powerpoint
1B

NSCLC cells were treated with CYH33 at the indicated concentrations for 1 h. Cell lysates were subjected to Western blot with the indicated antibodies.

  • Received November 25, 2019.
  • Accepted November 28, 2019.
  • Copyright: © 2019, Cancer Biology & Medicine
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    1. Wang YX,
    2. Li X,
    3. Liu XL,
    4. Chen Y,
    5. Yang CH,
    6. Tan C, et al.
    Simultaneous inhibition of pi3k alpha and cdk4/6 synergistically suppresses kras-mutated non-small cell lung cancer. Cancer Biol Med 2019; 16: 66–83.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 16 (4)
Cancer Biology & Medicine
Vol. 16, Issue 4
1 Nov 2019
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Erratum to Simultaneous inhibition of PI3Ka and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Erratum to Simultaneous inhibition of PI3Ka and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
Yuxiang Wang, Xian Li, Xueling Liu, Yi Chen, Chunhao Yang, Cun Tan, Bobo Wang, Yiming Sun, Xi Zhang, Yinglei Gao, Jian Ding, Linghua Meng
Cancer Biology & Medicine Nov 2019, 16 (4) 836; DOI: 10.20892/j.issn.2095-3941.2019.0401

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Erratum to Simultaneous inhibition of PI3Ka and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer
Yuxiang Wang, Xian Li, Xueling Liu, Yi Chen, Chunhao Yang, Cun Tan, Bobo Wang, Yiming Sun, Xi Zhang, Yinglei Gao, Jian Ding, Linghua Meng
Cancer Biology & Medicine Nov 2019, 16 (4) 836; DOI: 10.20892/j.issn.2095-3941.2019.0401
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Erratum to Treatment strategies for patients with HER2-positive gastric cancer
  • Erratum to Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA
  • Erratum to Intercellular transmission of cGAS-STING signaling in cancer
Show more Erratum

Similar Articles

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2025 Cancer Biology & Medicine

Powered by HighWire